HomeQuality and Safety in Pharmaceutical Development

Quality and Safety in Pharmaceutical Development

Drug characterization and release testing constitute pivotal stages in the pharmaceutical development process. Through the utilization of comprehensive analytical techniques and methodologies, pharmaceutical companies can safeguard the quality, safety, and effectiveness of their drugs. Collaborating with specialized testing laboratories can offer the essential expertise and resources required to conduct precise and dependable testing. These processes, encompassing drug characterization and release testing, enable pharmaceutical companies to fulfill regulatory mandates, assure patient safety, and introduce top-tier drugs to the market.

Drug Characterization and Release Testing

Drug characterization and release testing stand as indispensable phases in the development of pharmaceutical products. These procedures entail a thorough examination of drug substances and drug products to guarantee their quality, safety, and effectiveness. Through the assessment of critical quality attributes (CQAs), detection of impurities, and evaluation of drug stability, manufacturers can ascertain that their products align with regulatory requirements and are suitable for patient utilization.

Analytical Method Development

Analytical method development constitutes a pivotal element of drug characterization and release testing. It encompasses the formulation, validation, and transfer of analytical methods tailored to accurately evaluate the quality and purity of drug substances and drug products. Through method development, scientists can identify the most suitable techniques and instruments for analyzing specific drugs, factoring in considerations like molecular structure and the compound’s distinctive attributes.

The review or determination of critical quality attributes (CQAs) for the developed molecule entails the selection of appropriate methods based on the developmental stage, intended purpose, and a risk-based approach. Subsequently, the chosen methods must undergo validation and qualification following good manufacturing practices (GMP) guidelines.

Drug characterization encompasses a comprehensive analysis of the drug substance or drug product, encompassing structural characterization, impurity profiling, and physicochemical assessments. This exhaustive characterization yields valuable insights into the composition and quality of the drug.

Analytical Techniques in Drug Characterization

Drug characterization relies on a diverse array of analytical techniques to evaluate the quality and purity of drug substances and drug products. These encompass Mass Spectrometry, utilized for structural characterization, identification of impurities, and determination of post-translational modifications. Another method is High-Performance Liquid Chromatography (HPLC), which segregates sample components based on their chemical properties, enabling the quantification of impurities, degradation products, and active pharmaceutical ingredients (APIs). Glycan analysis pertains to the characterization of carbohydrate structures linked to proteins. Lastly, bioassays, measuring the biological response of a drug in living organisms or cells, are pivotal for ensuring the desired therapeutic effect.

GMP Release and Stability Testing

GMP release and stability testing constitute pivotal phases in the drug development process. These tests are instrumental in ensuring that the manufactured drug products adhere to the requisite quality standards and are safe for patient utilization. GMP release testing encompasses a series of assays designed to ascertain the content, impurities, identity, purity, potency, and excipients of the drug product.

Stability testing stands as another indispensable facet of GMP testing. It entails subjecting the drug product to various storage conditions to assess its stability over time. Stability studies evaluate factors such as pH, appearance, potency, and sterility to ascertain the drug’s shelf life and provide recommendations for its storage.


Arvinas goes public to bring its PROTAC-based anticancer drug to the market looking at an $100 mn IPO